NGeneBio Co., Ltd. (KOSDAQ:354200)

South Korea · Delayed Price · Currency is KRW

2,275.00

+278.00 (13.92%)

At close: Aug 11, 2026

-60.87% (1Y)

Market Cap	20.33B -58.1%
Revenue (ttm)	31.20B +363.7%
Net Income	-7.00B
EPS	-873.48
Shares Out	8.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,547,983
Open	2,190.00
Previous Close	1,997.00
Day's Range	2,170.00 - 2,595.00
52-Week Range	1,443.00 - 8,295.00
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 354200

Full Company Profile

Financial Performance

In 2025, NGeneBio's revenue was 21.24 billion, an increase of 278.54% compared to the previous year's 5.61 billion. Losses were -5.54 billion, -57.29% less than in 2024.

Financial Statements